Drugs / Avaxim 80
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07183371 Comparator | Dec 2025 → Dec 2026 expected | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Avaxim 80 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07183371 ↗ |
| Modality | Vaccine | “Avaxim 80 is an inactivated, adsorbed hepatitis A vaccine” NCT07183371 ↗ |
| Route | Intramuscular | “the Hepatitis A vaccine, Avaxim 80, which will be given at Month 0 (Day 0) and Month 6 (Day 182), the meningitis vaccine, Menveo, given at Month 1 (Day 28), and a rabies...” NCT07183371 ↗ |